Planning Strategies’s 4D Molecular Therapeutics FDMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.18K Hold
502
– – ﹤0.01% 383
2026
Q2
$6.68K Buy
+502
New +$4.89K ﹤0.01% 385

Other funds holding FDMT

Planning Strategies's FDMT Position: Q3 2026 in Review

Planning Strategies held its 4D Molecular Therapeutics (FDMT) position steady in Q3 2026 at 502 shares worth $7.18K. The position accounts for ﹤0.01% of the portfolio, ranked #383.

Planning Strategies first reported a position in FDMT in Q2 2026 and has held it in 2 quarters since. 166 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Planning Strategies held 502 shares of 4D Molecular Therapeutics worth $7.18K as of Q3 2026.
  • Planning Strategies left its 4D Molecular Therapeutics share count unchanged in Q3 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Planning Strategies's portfolio in Q3 2026, its #383 holding.
  • Planning Strategies first reported a position in 4D Molecular Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 166 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Planning Strategies's 13F filing for Q3 2026, filed 2 Oct 2026.